A Study of TAVO412 in Patients with Cancer (TAVO412)
- First Posted Date
- 2025-01-07
- Last Posted Date
- 2025-01-16
- Lead Sponsor
- Tavotek Biotherapeutics
- Target Recruit Count
- 50
- Registration Number
- NCT06761651
- Locations
- ๐จ๐ณ
Affiliated Cancer Hospital of Chongqing University, Chongqing, Chongqing, China
๐จ๐ณFirst Affiliated Hospital of Xiamen University, Xiamen, Fujian, China
๐จ๐ณZhujiang Hospital of Southern Medical University, Guangzhou, Guangdong, China
A Study of TAVO101 in Atopic Dermatitis Patients
- First Posted Date
- 2023-12-19
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Tavotek Biotherapeutics
- Target Recruit Count
- 20
- Registration Number
- NCT06176040
- Locations
- ๐ฆ๐บ
Royal Melbourne Hospital, Parkville, Victoria, Australia
๐ณ๐ฟOptimal Clinical Trials, Auckland, New Zealand
A Study of TAVO412 in Patients with Cancer
- First Posted Date
- 2022-09-21
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- Tavotek Biotherapeutics
- Target Recruit Count
- 50
- Registration Number
- NCT05548634
- Locations
- ๐บ๐ธ
Tisch Cancer Center, NYC, New York, United States
Study of TAVO103A in Healthy Volunteers
- First Posted Date
- 2022-04-06
- Last Posted Date
- 2023-12-12
- Lead Sponsor
- Tavotek Biotherapeutics
- Target Recruit Count
- 30
- Registration Number
- NCT05313152
- Locations
- ๐บ๐ธ
ICON, Salt Lake City, Utah, United States
Study of TAVO101 in Healthy Volunteers
Phase 1
Completed
- Conditions
- Healthy Subjects
- First Posted Date
- 2022-03-28
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Tavotek Biotherapeutics
- Target Recruit Count
- 42
- Registration Number
- NCT05298046
- Locations
- ๐ฆ๐บ
CMAX Clinical Research Pty Ltd, Adelaide, South Australia, Australia
ยฉ Copyright 2025. All Rights Reserved by MedPath